Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, notes today that its portfolio company, Achilles Therapeutics has..
Syncona Limited (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today announced a $51.0 million new commitment in a..
Syncona Ltd (LON: SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, has noted that its portfolio company, Autolus Therapeutics plc today announced..
Syncona Ltd (LON: SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today announced that it has made a $80.0 million commitment in..
Syncona Ltd (LON: SYNC) has today announced a new portfolio company, Azeria Therapeutics in a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life sciences, today announced that it has committed £48.0 million of a £50.4 million..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today issued its quarterly update covering the period from 1 April to..
Syncona Limited (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, announced that Melanie Gee has been appointed to the Group’s Board of..
Syncona Ltd (LON:SYNC) announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, is pleased to note that its portfolio company, Blue Earth Diagnostics (Blue..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today announces the merger of its companies, Gyroscope Therapeutics (Gyroscope), an ophthalmology..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today notes that its portfolio company, Autolus Therapeutics plc has filed a..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today noted the announcement from its company, Nightstar Therapeutics Plc (NASDAQ:NITE) (Nightstar),..
Syncona Ltd (LON:SYNC) announced a CHF 28 million (£21.4 million) commitment to Anaveon, a new immuno-oncology company, in a CHF 35 million (£26.8 million) Series A financing alongside the Novartis..
Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today issues its quarterly update covering the period from 1 October to..
Syncona Limited (LON:SYNC), today announced Interim Results for the six months ended 30 September 2018. Life science companies continue to drive strong returns and increase in NAV · Net assets..
